What’s New in Myeloma Research?
Along with expert panelists, IMF Chief Medical Officer Dr. Joseph Mikhael will discuss important Top Myeloma Research and Key Takeaways from the 2024 American Society of Hematology (ASH) Conference. Of the more than 8,500 abstracts “representing the most cutting-edge science in hematology” presented at the 2024 ASH meeting, over 1,000 abstracts were related to multiple myeloma.
In this webinar, IMF Chief Medical Officer Dr. Joseph Mikhael will host a panel discussion highlighting the patient perspective with IMF Support Group Leaders, patient advocates and members of The IMF 2024 Myeloma Voices at ASH Team, Sheri Baker (Treasure Valley Multiple Myeloma Support Group), Terry Glassman (Long Island Multiple Myeloma Informational Support Group), and Rob Salmon (SF Bay Area MM Support Group).
Some of the topics of utmost interest to the myeloma community include the following:
- Latest myeloma treatments and results of ongoing clinical trials
- Advances in CAR T Cell therapy and bispecific antibodies
- New developments in MRD (minimal residual disease) testing
- Patient Centric topics like quality-of-life studies and patient preferences research
- Other 2024 Hot Topics critical topics such as real-world data, drug access, and health disparities
Dr. Mikhael explains this data in approachable terms that patients and care partners can use in their everyday care decision-making. The webinar will conclude with a summary discussion and closing remarks. At the end of the presentation, participants will have time to ask questions through a Live Q&A.
